8-K: Barinthus Bio Announces Topline Results from Phase 1b/2 APOLLO Trial of VTP-200 for HPV Infections

Barinthus Biotherapeutics' APOLLO trial of VTP-200 for HPV infections met its primary safety endpoint, showing positive trends in high-dose groups but no statistically significant improvement overall compared to placebo.

Summary

• Barinthus Biotherapeutics announced topline data from the APOLLO trial, a Phase 1b/2 study of VTP-200 in women with persistent high-risk HPV infections and low-grade cervical lesions.
• The trial included 108 participants across the UK and EU and evaluated the safety, tolerability, and immunogenicity of VTP-200.
• The primary objective of the trial was to assess the safety and tolerability of VTP-200, which was met with the treatment being generally well-tolerated.
• The study also aimed to evaluate the effect of VTP-200 on the clearance of hrHPV infection and cervical lesions.
• The highest hrHPV clearance rate of 60% was observed in group 2, which received the highest dose of ChAdOx, compared to 33% in the placebo group.
• The highest cervical lesion clearance rate of 67% was observed in groups 2 and 5, both receiving the highest dose of ChAdOx, compared to 39% in the placebo group.
• However, pooled data from all active dose groups showed no statistically significant improvement in hrHPV or cervical lesion clearance compared to the placebo group.
• The company is conducting further analyses, particularly focusing on immunological responses, and plans to share detailed results later.

Sentiment

Score: 5

Explanation: The document presents mixed results. While the safety profile is positive and there are encouraging trends in the high-dose groups, the lack of statistical significance in the pooled data tempers the overall sentiment. The company is still in the early stages of development and faces significant risks.

Positives

• VTP-200 was generally well-tolerated, meeting the primary safety endpoint of the study.
• The highest dose groups showed promising trends in hrHPV and cervical lesion clearance rates.
• The study provides valuable information for future development of VTP-200, particularly regarding dosing.

Negatives

• Pooled data from all active dose groups did not show a statistically significant improvement in hrHPV or cervical lesion clearance compared to the placebo group.
• The trial was not powered for individual dose group comparisons, limiting the statistical significance of the results.

Risks

• The lack of statistically significant improvement in pooled data may impact the future development of VTP-200.
• The company faces risks related to the success, cost, and timing of its pipeline development activities and clinical trials.
• There are risks associated with regulatory developments and the company's ability to fund its operations and access capital.
• Global economic uncertainty, including disruptions in the banking industry and geopolitical conflicts, could affect the company's operations.

Future Outlook

The company is evaluating future development options for the VTP-200 program and conducting further analyses, particularly focusing on immunological responses. They plan to share detailed results in due course.

Management Comments

• Bill Enright, Chief Executive Officer of Barinthus Bio, stated that while they didn't observe a significant improvement from VTP-200 in the overall pooled results, they did observe positive trends in the highest dose cohorts.
• Nadege Pelletier, Chief Scientific Officer of Barinthus Bio, mentioned that the most promising hrHPV and cervical lesion clearance data were observed in the highest ChAdOx-HPV dosing groups, which is informative for future development.

Industry Context

This announcement is relevant to the broader field of immunotherapies for HPV-related diseases, where there is a need for non-surgical treatments for persistent infections and pre-cancerous lesions. The results will be of interest to companies developing similar therapies and to the medical community focused on cervical cancer prevention and treatment.

Comparison to Industry Standards

• The 60% hrHPV clearance rate in the highest dose group is a positive signal, but needs to be compared to other HPV therapeutic trials.
• The 67% cervical lesion clearance rate in the highest dose groups is also encouraging, but the lack of statistical significance in pooled data is a concern.
• Companies like Inovio Pharmaceuticals and Advaxis are also developing HPV immunotherapies, and their results will be important to compare against Barinthus Bio's findings.
• The safety profile of VTP-200 appears favorable compared to some other immunotherapies, which often have higher rates of adverse events.

Stakeholder Impact

• Shareholders may react cautiously to the mixed results, with the lack of statistical significance in pooled data being a concern.
• Patients with HPV infections and low-grade cervical lesions may be hopeful about the potential of VTP-200, but further development is needed.
• The medical community will be interested in the detailed results and further development of the therapy.

Next Steps

• The company will conduct further analyses, focusing on immunological responses.
• The company will evaluate future development options for the VTP-200 program.
• The company plans to share detailed results in due course.

Key Dates

Keywords

VTP-200, HPV, Cervical Cancer, Immunotherapy, Clinical Trial, APOLLO, ChAdOx, MVA, T cell, Biopharmaceutical